drug_type
RELEVANT_DRUG
intervention_type
Biologic drug (anti-HER2 monoclonal antibody)
drug_description
Recombinant humanized anti-HER2 monoclonal antibody that binds HER2, augments HER2 pathway blockade, and promotes ADCC.
nci_thesaurus_concept_id
C172198
nci_thesaurus_definition
A humanized immunoglobulin (lg) G1 monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2), with potential immunomodulating and antineoplastic activity. Upon administration, anti-HER2 monoclonal antibody HLX22 targets and binds to HER2 on tumor cell surface. This may induce a cytotoxic T-lymphocyte (CTL) response as well as an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that overexpress HER2. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 monoclonal antibody targeting HER2/ERBB2 on tumor cells; binds the extracellular domain to block HER2 signaling/heterodimerization and enhances pathway blockade, while engaging Fcγ receptors to mediate antibody‑dependent cellular cytotoxicity (ADCC) against HER2‑overexpressing cells.
drug_name
HLX22
nct_id_drug_ref
NCT06532006